RT Journal Article
SR Electronic
T1 Induction of trained immunity by influenza vaccination - impact on COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.03.21263028
DO 10.1101/2021.09.03.21263028
A1 Priya A. Debisarun
A1 Katharina L. Gössling
A1 Ozlem Bulut
A1 Gizem Kilic
A1 Martijn Zoodsma
A1 Zhaoli Liu
A1 Marina Oldenburg
A1 Nadine Rüchel
A1 Bowen Zhang
A1 Cheng-Jian Xu
A1 Patrick Struycken
A1 Valerie A.C.M. Koeken
A1 Jorge Domínguez-Andrés
A1 Simone J.C.F.M. Moorlag
A1 Esther Taks
A1 Philipp N. Ostermann
A1 Lisa Müller
A1 Heiner Schaal
A1 Ortwin Adams
A1 Arndt Borkhardt
A1 Jaap ten Oever
A1 Reinout van Crevel
A1 Yang Li
A1 Mihai G. Netea
YR 2021
UL http://medrxiv.org/content/early/2021/09/10/2021.09.03.21263028.abstract
AB Non-specific protective effects of certain vaccines have been reported, and long-term boosting of innate immunity, termed trained immunity, has been proposed as one of the mechanisms mediating these effects. Several epidemiological studies suggested cross-protection between influenza vaccination and COVID-19. In a large academic Dutch hospital, we found that SARS-CoV-2 infection was less common among employees who had received a previous influenza vaccination: relative risk reductions of 37% and 49% were observed following influenza vaccination during the first and second COVID-19 waves, respectively. The quadrivalent inactivated influenza vaccine induced a trained immunity program that boosted innate immune responses against various viral stimuli and fine-tuned the anti-SARS-CoV-2 response, which may result in better protection against COVID-19. Influenza vaccination led to transcriptional reprogramming of monocytes and reduced systemic inflammation. These epidemiological and immunological data argue for potential benefits of influenza vaccination against COVID-19, and future randomized trials are warranted to test this possibility.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMGN was supported by a Spinoza Grant of the Netherlands Association for Scientific Research and an ERC Advanced Grant (#833247). YL was supported by an ERC starting Grant (#948207) and a Radboud University Medical Centre Hypatia Grant (2018). PNO, LM and HS were supported by the Jurgen Manchot Foundation. KLG was supported by the German Research Foundation (DFG # 428917761). MO was supported by the Research Committee of the Heinrich Heine University Duesseldorf. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Observational study: The Radboudumc databases on influenza vaccination status and COVID-19 incidence among employees were provided by the Department of Occupational Health and Safety. Giving the observational nature of this study, ethical waiver was obtained from the Arnhem-Nijmegen Ethical Committee. Ex-vivo study: . Ethical approval was obtained from the Duesseldorf Ethical Committee (study ID 2018_199, amendment 2018-199_1- (5/2020), and amendment 2018_199_2 (12/2020)).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes(Single-cell) sequencing data have been deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGAS00001005446. Olink proteomics data have been deposited to the Immport database under the study number SDY1799.